Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 26, 2026
DataAggregated Company Financials
Companies20
  • 7D10.3%
  • 3M29.1%
  • 1Y-22.8%
  • YTD-6.7%

The Healthcare industry is up 10% in the last week, with Novo Nordisk up 13%. However, the industry is down 23% over the past year. Looking forward, earnings are forecast to grow by 2.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Jun 2026DKK 1.8tDKK 469.3bDKK 147.2b19.8x12.4x3.9x
Sun, 24 May 2026DKK 1.7tDKK 468.7bDKK 147.0b20.4x11.6x3.6x
Tue, 21 Apr 2026DKK 1.6tDKK 447.1bDKK 129.9b19.6x12.1x3.5x
Thu, 19 Mar 2026DKK 1.5tDKK 447.9bDKK 130.1b16.4x11.4x3.3x
Sat, 14 Feb 2026DKK 1.8tDKK 448.0bDKK 134.8b15.7x13.5x4.1x
Mon, 12 Jan 2026DKK 2.2tDKK 454.0bDKK 137.0b17.9x16.1x4.9x
Wed, 10 Dec 2025DKK 1.8tDKK 454.0bDKK 137.0b17x13.3x4x
Fri, 07 Nov 2025DKK 1.9tDKK 451.7bDKK 134.4b17.8x13.8x4.1x
Sun, 05 Oct 2025DKK 2.2tDKK 447.3bDKK 141.7b18.3x15.5x4.9x
Tue, 02 Sep 2025DKK 2.1tDKK 447.4bDKK 141.7b24.4x14.9x4.7x
Thu, 31 Jul 2025DKK 1.9tDKK 423.8bDKK 124.7b29.5x15.2x4.5x
Sat, 28 Jun 2025DKK 2.4tDKK 423.1bDKK 124.5b30.5x19.2x5.7x
Mon, 26 May 2025DKK 2.4tDKK 424.3bDKK 125.1b23.4x19.4x5.7x
Wed, 23 Apr 2025DKK 2.2tDKK 409.2bDKK 121.3b20.8x17.9x5.3x
Fri, 21 Mar 2025DKK 2.9tDKK 409.5bDKK 121.3b25.2x24x7.1x
Sun, 16 Feb 2025DKK 3.0tDKK 409.9bDKK 121.5b26.3x24.9x7.4x
Tue, 14 Jan 2025DKK 3.3tDKK 387.5bDKK 111.4b29.4x29.4x8.4x
Thu, 12 Dec 2024DKK 4.1tDKK 387.4bDKK 111.3b31.2x36.5x10.5x
Sat, 09 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b32.7x35.1x10.1x
Mon, 07 Oct 2024DKK 4.0tDKK 372.0bDKK 107.1b35.8x37.5x10.8x
Wed, 04 Sep 2024DKK 4.7tDKK 372.0bDKK 107.2b35x44.2x12.7x
Fri, 02 Aug 2024DKK 4.7tDKK 355.4bDKK 106.3b36.7x44x13.2x
Sun, 30 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.1x47.4x14.2x
Tue, 28 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.4x43.8x13.1x
Thu, 25 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b33.8x45.1x13.2x
Sat, 23 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.7x45.7x13.4x
Mon, 19 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.9x44.3x12.9x
Wed, 17 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.4x42.1x11.8x
Fri, 15 Dec 2023DKK 3.5tDKK 320.4bDKK 90.0b33.2x38.7x10.9x
Sun, 12 Nov 2023DKK 3.6tDKK 319.8bDKK 89.9b31.7x39.6x11.1x
Tue, 10 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b32.5x41x11x
Thu, 07 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.2x42.6x11.5x
Sat, 05 Aug 2023DKK 2.9tDKK 288.2bDKK 74.9b38.5x38.6x10x
Mon, 03 Jul 2023DKK 3.0tDKK 287.1bDKK 75.5b40.3x39.9x10.5x
Price to Earnings Ratio

39.9x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.4x which is lower than its 3-year average PE of 29.4x.
  • The 3-year average PS ratio of 8.5x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market5.69%
Healthcare10.32%
Pharma11.83%
Healthcare Services11.49%
Biotech4.36%
Medical Equipment3.88%
Life Sciences-2.47%
Healthtech-5.23%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.0x.
    • Analysts are expecting annual earnings growth of 19.9%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 317.558.4%
+DKK 109.0b		-27.4%PE11.5x
GMAB GenmabDKK 1.70k3.8%
+DKK 3.8b		29.7%PE19.4x
DEMANT DemantDKK 265.807.3%
+DKK 3.8b		0.6%PE23.7x
HLUN B H. LundbeckDKK 42.161.5%
+DKK 634.4m		18.0%PE11.2x
COLO B ColoplastDKK 380.700.5%
+DKK 427.8m		-36.8%PE40.7x

Latest News

ZEAL
DKK 283.70
Zealand Pharma
7D
1.1%
1Y
-21.2%
Narrative Update • Jun 25

ZEAL: Obesity Pipeline Progress And Buybacks Will Support Future Re Rating

Zealand Pharma's analyst price target has moved from about DKK 825 to roughly DKK 300, as analysts point to a longer timeline to unlock upside, lower peak sales expectations for key pipeline drugs, and revised assumptions that include a higher future P/E multiple and softer projected growth and margins. Analyst Commentary Recent Street research on Zealand Pharma highlights a mix of caution and optimism, with several analysts revisiting their assumptions on valuation, execution timelines, and the growth potential of key pipeline assets such as petrelintide and survodutide.
GMAB
DKK 1,699.00
Genmab
7D
3.8%
1Y
29.7%
Narrative Update • Jun 25

GMAB: Upcoming Oncology Readouts Will Test Commercial Model And Earnings Resilience

Genmab's analyst price targets have been revised lower, with one recent DKK target cut from DKK 48 to DKK 40, as analysts factor in updated assumptions for revenue growth, margins and long term P/E. They still point to the company's shift toward a commercially driven platform and upcoming data readouts for Epkinly, Rina-S and petosemtamab as key drivers in the story.
NOVO B
DKK 317.55
Novo Nordisk
7D
8.4%
1Y
-27.4%
EMBLA
DKK 26.00
Embla Medical hf
7D
-2.4%
1Y
-22.6%
Narrative Update • Jun 24

EMBLA: Recent Buybacks Will Support Future Upside Potential

Analysts have kept their DKK price target for Embla Medical hf broadly steady, with only a marginal adjustment that reflects small tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Embla Medical hf reported completion of a share repurchase program covering 556,103 shares, equivalent to 0.13% of the company, for a total consideration of $2.6 million.
HLUN B
DKK 42.16
H. Lundbeck
7D
1.5%
1Y
18.0%
GUBRA
DKK 319.20
Gubra
7D
-5.5%
1Y
-39.3%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
DEMANT
DKK 265.80
Demant
7D
7.3%
1Y
0.6%
Narrative Update • Jun 23

DEMANT: Fair Value View Balances Growth Inflection Hopes With Execution Risks

Analysts have lifted their price expectations for Demant, with the consensus fair value estimate moving from DKK 240.32 to DKK 251.11. Recent research points to a higher price target range supported by updated views on growth, profitability and future P/E multiples.
ALK B
DKK 251.20
ALK-Abelló
7D
0.5%
1Y
35.6%
AMBU B
DKK 60.90
Ambu
7D
-3.3%
1Y
-39.3%
Narrative Update • Jun 17

AMBU B: Bearish Downgrade And Stable Assumptions May Support Future Repricing

Analysts have reduced their price target on Ambu shares to DKK 88.8, citing a more cautious stance reflected in recent research, including a downgrade from Danske Bank. This comes even as underlying model inputs such as the discount rate, growth and future P/E assumptions remain broadly unchanged.
COLO B
DKK 380.70
Coloplast
7D
0.5%
1Y
-36.8%
Narrative Update • Jun 16

COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating

The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.
BAVA
DKK 178.30
Bavarian Nordic
7D
1.6%
1Y
5.3%
Narrative Update • Jun 15

BAVA: Public Preparedness Contracts Will Support 2026 Earnings Upside

Analysts have kept their DKK 273.33 price target for Bavarian Nordic broadly unchanged, citing only minor adjustments to the discount rate, revenue growth assumptions and future P/E estimates in their valuation work. What's in the News Bavarian Nordic secured a government contract valued at over DKK 700 million to supply its MVA-BN smallpox/mpox vaccine in 2026 and 2027, bringing Public Preparedness business contracts for 2026 to about DKK 2,200 million (Source: company announcement, recent news reports).
MONSO
DKK 0.32
Monsenso
7D
-31.6%
1Y
-1.8%
BIOPOR
DKK 1.12
BioPorto
7D
-4.3%
1Y
-22.8%
NNIT
DKK 36.90
NNIT
7D
-9.3%
1Y
-46.1%
CHEMM
DKK 372.80
ChemoMetec
7D
-1.4%
1Y
-34.4%
STENO
DKK 1.00
Stenocare
7D
-8.7%
1Y
72.4%